Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment

Cancer Research

Volumn 57, Issue 4, 1997, Pages 708-713

  Lebowitz, Peter F ^a   Sakamuro, Daitoku ^a   Prendergast, George C ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b WISTAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FARNESYL TRANS TRANSFERASE;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; CELL ADHESION; CELL DEATH; CELL DENSITY; CELL GROWTH; CELL TRANSFORMATION; CELL VIABILITY; ENZYME INDUCTION; ENZYME INHIBITION; HUMAN; HUMAN CELL; ONCOGENE RAS; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; TARGET CELL;

ALKYL AND ARYL TRANSFERASES; ANIMALS; APOPTOSIS; BCL-X PROTEIN; CELL ADHESION; CELL COUNT; CELL LINE, TRANSFORMED; CULTURE MEDIA; DOSE-RESPONSE RELATIONSHIP, DRUG; GENES, P53; GENES, RAS; OLIGOPEPTIDES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENES; RATS; TRANSFERASES;

EID: 0031050738     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Gibbs, J., Oliff, A., and Kohl, N. E. Farnesyltransferase inhibitors. Ras research yields a potential cancer therapeutic. Cell, 77: 175-178, 1994.
2. Lowy, D., and Willumsen, B. Regulators and effectors of Ras. Annu. Rev. Biochem., 62: 851-891, 1993.
3. Prendergast, G. C., and Gibbs, J. B. Pathways of Ras function: connections to the actin cytoskeleton. Adv. Cancer Res., 62: 19-63, 1993.
4. Bos, J. L. ras gene mutations and human cancer. In: J. Cossman (ed.), Molecular Genetics in Cancer Diagnosis, pp. 273-287. Amsterdam: Elsevier Science Publishers, B. V., 1990.
5. Der, C. J., and Cox, A. D. Isoprenoid modification and plasma membrane association: critical factors for Ras oncogenicity. Cancer Cells (Cold Spring Harbor), 3: 331-340, 1991.
6. Kato, K., Cox, A. D., Hisaka, M. M., Graham, S. M., Buss, J. E., and Der, C. J. Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc. Natl. Acad. Sci. USA, 89: 6403-6407, 1992.
7. Marshall, C. J. Protein prenylation: a mediator of protein-protein interactions. Science (Washington DC), 259: 1865-1866, 1993.
8. Gibbs, J. B. Ras C-terminal processing enzymes - new drug targets? Cell, 65: 1-4, 1991.
9. Lebowitz, P. F., Davide, J. P., and Prendergast, G. C. Evidence that farnesyl transferase inhibitors suppress Ras transformation by interfering with Rho activity. Mol. Cell. Biol., 15: 6613-6622, 1995.
10. Sepp-Lorenzino, L., Ma, Z., Rands, E., Kohl, N. E., Gibbs, J. B., Oliff, A., and Rosen, N. A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res., 55: 5302-5309, 1995.
11. James, G. L., Goldstein, J. L., Brown, M. S., Rawson, T. E., Somers, T. C., McDowell, R. S., Crowley, C. W., Lucas, B. K., Levinson, A. D., and Marsters, J. C. Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells. Science (Washington DC), 260: 1937-1942, 1993.
12. Prendergast, G. C., Davide, J. P., deSolms, S. J., Giuliani, E., Graham, S., Gibbs, J. B., Oliff, A., and Kohl, N. E. Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton. Mol. Cell. Biol., 14: 4193-4202, 1994.
13. Manne, V., Yan, N., Carboni, J. M., Tuomari, A. V., Ricca, C. S., Brown, J. G., Andahazy, M. L., Schmidt, R. J., Patel, D., Zahler, R., Weinmann, R., Der, C. J., Cox, A. D., Hunt, J. T., Gordon, E. M., Barbacid, M., and Seizinger, B. R. Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras-transformed cells. Oncogene, 10: 1763-1779, 1995.
14. Kohl, N. E., Redner, F., Mosser, S., Guiliani, E. A., deSolms, S. J., Conner, M. W., Anthony, N. J., Holtz, W. J., Gomez, R. P., Lee, T-J., Smith, R. L., Graham, S. L., Hartman, G. D., Gibbs, J., and Oliff, A. Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc. Natl. Acad. Sci. USA, 91: 9141-9145, 1994.
15. Nagasu, T., Yoshimatsu, K., Rowell, C., Lewis, M. D., and Garcia, A. M. Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956. Cancer Res., 55: 5310-5314, 1995.
16. Kohl, N. E., Omer, C. A., Conner, M. W., Anthony, N. J., Davide, J. P., deSolms, S. J., Giuliani, E. A., Gomez, R. P., Graham, S. L., Hamilton, K., Handt, L. K., Hartman, G. D., Koblan, K. S., Kral, A. M., Miller, P. J., Mosser, S. D., O'Neill, T. J., Rands, E., Schaber, M. D., Gibbs, J. B., and Oliff, A. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat. Med. 1: 792-797, 1995.
17. Michalovitz, D., Halevy, O., and Oren, M. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell, 62: 671-681, 1990.
18. Sakamuro, D., Eviner, V., Elliott, K., Showe, L., White, E., and Prendergast, G. C. c-Myc induces apoptosis in epithelial cells by p53-dependent and p53-independent mechanisms. Oncogene, 11: 2411-2418, 1995.
19. Harlow, E., and Lane, D. Antibodies: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1988.
20. Frisch, S. M., and Francis, H. Disruption of epithelial cell-matrix interactions induces apoptosis. J. Cell Biol., 124: 619-626, 1994.
21. Korsmeyer, S. J. Regulators of cell death. Trends Genet., 11: 101-105, 1995.
22. White, E. Life, death, and the pursuit of apoptosis. Genes & Dev., 10: 1-15, 1996.
23. Krajewska, M., Moss, S. F., Krajewski, S., Song, K., Holt, P. R., and Reed, J. C. Elevated expression of Bcl-X and reduced Bak in primary colorectal adenocarcinomas. Cancer Res., 56: 2422-2427, 1996.
24. Ko, L. J., and Prives, C. p53: puzzle and paradigm. Genes & Dev., 10: 1054-1072, 1996.
25. Prendergast, G. C., Khosravi-Far, R., Solski, P., Kurzawa, K, Lebowitz, P., and Der, C. J. Critical role of Rho in cell transformation by oncogenic Ras. Oncogene, 10: 2289-2296, 1995.
26. Prendergast, G. C., Davide, J. P., Lebowitz, P. F., Wechsler-Reya, R., and Kohl, N. E. Resistance of a variant ras-transformed cell line to phenotypic reversion by farnesyl transferase inhibitors. Cancer Res., 56: 2626-2632, 1996.
27. Aepfelbacher, M. ADP-ribosylation of Rho enhances adhesion of U937 cells to fibronectin via the α5 β integrin receptor. FEBS Lett., 363: 78-80, 1995.
28. Hotchin, N. A., and Hall, A. The assembly of integrin adhesion complexes requires both extracellular matrix and intracellular rho/rac GTPases. J. Cell Biol., 131: 1857-1865, 1995.
29. Laudanna, C., Campbell, J. J., and Butcher, E. C. Role of Rho in chemoattractant-activated leukocyte adhesion through integrins. Science (Washington DC), 271: 981-983, 1996.
30. Ruoslahti, E., and Reed, J. C. Anchorage dependence, integrins, and apoptosis. Cell, 77: 477-478, 1994.
31. Udagawa, T., and McIntyre, B. W. ADP-ribosylation of the G protein Rho inhibits integrin regulation of tumor cell growth. J. Biol. Chem., 271: 12542-12548, 1996,
32. Ridley, A. J., and Hall, A. The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell, 70: 389-399, 1992.
33. Khosravi-Far, R., Solski, P. A., Clark, G. J., Kinch, M. S., and Der, C. J. Activation of Rac1, RhoA, and mitogen-activated protein kinase are required for Ras transformation. Mol. Cell. Biol., 75: 6443-6453, 1995.
34. Qiu, R. G., Chen, J., McCormick, F., and Symons, M. A role for Rho in Ras transformation. Proc. Natl. Acad. Sci. USA, 92: 11781-11785, 1995.
35. rho proteins. J. Cell Biol., 119: 617-627, 1992.
36. Murphy, C., Saffrich, R., Grummt, M., Gournier, H., Rybin, V., Rubino, M., Auvinen, P., Lütcke, A., Parton, R., and Zerial, M. Endosome dynamics regulated by a rho protein. Nature, 384: 427-432, 1996.